Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 7/2010

01-07-2010 | Original Paper

MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects

Authors: Chen Mao, Li-Xin Qiu, Ping Zhan, Kai Xue, Hong Ding, Fang-Bing Du, Jin Li, Qing Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2010

Login to get access

Abstract

Purpose

Published data on the association between manganese superoxide dismutase (MnSOD) Val16Ala polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimate of the association between them, a meta-analysis was performed.

Methods

PubMed and Embase were searched. All eligible studies were retrieved. The pooled odds ratio (OR) with 95% confidence interval (CI) for PCA risk associated with Val/Ala versus Val/Val, Ala/Ala versus Val/Val, dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val) were estimated, respectively.

Results

A total of 12 studies including 8,962 subjects were involved in this meta-analysis. Overall, the meta-analysis indicated that significantly elevated cancer risk was associated with Ala variant genotype when all the eligible studies were pooled into the meta-analysis (for Val/Ala vs. Val/Val: OR = 1.11, 95% CI = 1.00–1.24; for Ala/Ala vs. Val/Val: OR = 1.22, 95% CI = 1.00–1.49; for dominant model: OR = 1.14, 95% CI = 1.03–1.26). In the subgroup analysis by ethnicity, statistically significant increased risks were found among Caucasians with Ala allele (for Val/Ala vs. Val/Val: OR = 1.12, 95% CI = 1.00–1.25; for dominant model: OR = 1.14, 95% CI = 1.02–1.26). However, no significant associations were found in Africans.

Conclusions

This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.
Literature
go back to reference Arsova-Sarafinovska Z, Matevska N, Petrovski D et al (2008) Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct 26:771–777CrossRefPubMed Arsova-Sarafinovska Z, Matevska N, Petrovski D et al (2008) Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct 26:771–777CrossRefPubMed
go back to reference Arundhati B, Niladri B (2008) Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev 17:3298–3305CrossRef Arundhati B, Niladri B (2008) Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev 17:3298–3305CrossRef
go back to reference Baker AM (1997) Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32:229–233CrossRefPubMed Baker AM (1997) Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32:229–233CrossRefPubMed
go back to reference Bica CG, da Silva LL, Toscani NV et al (2009) MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res 15:19–24CrossRefPubMed Bica CG, da Silva LL, Toscani NV et al (2009) MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res 15:19–24CrossRefPubMed
go back to reference Choi JY, Neuhouser ML, Barnett M et al (2007) Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 16:1115–1120CrossRefPubMed Choi JY, Neuhouser ML, Barnett M et al (2007) Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 16:1115–1120CrossRefPubMed
go back to reference Choi JY, Neuhouser ML, Barnett MJ et al (2008) Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29:964–970CrossRefPubMed Choi JY, Neuhouser ML, Barnett MJ et al (2008) Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29:964–970CrossRefPubMed
go back to reference Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef
go back to reference Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE (2003) MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 5:677–688CrossRefPubMed Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE (2003) MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 5:677–688CrossRefPubMed
go back to reference Egger M, Smith DG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629–634PubMed Egger M, Smith DG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629–634PubMed
go back to reference Ergen HA, Narter F, Timirci O, Isbir T (2007) Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case–control study. Anticancer Res 27:1227–1230PubMed Ergen HA, Narter F, Timirci O, Isbir T (2007) Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case–control study. Anticancer Res 27:1227–1230PubMed
go back to reference Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–51CrossRefPubMed Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–51CrossRefPubMed
go back to reference Iguchi T, Wang CY, Delongchamps NB et al (2008) Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology 72:238–241. Discussion 241–242CrossRefPubMed Iguchi T, Wang CY, Delongchamps NB et al (2008) Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology 72:238–241. Discussion 241–242CrossRefPubMed
go back to reference Iguchi T, Sugita S, Wang CY, Newman NB, Nakatani T, Haas GP (2009) MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo 23:7–12PubMed Iguchi T, Sugita S, Wang CY, Newman NB, Nakatani T, Haas GP (2009) MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo 23:7–12PubMed
go back to reference Kang D, Lee KM, Park SK et al (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16:1581–1586CrossRefPubMed Kang D, Lee KM, Park SK et al (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16:1581–1586CrossRefPubMed
go back to reference Li N (1998) Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35:221–233CrossRefPubMed Li N (1998) Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35:221–233CrossRefPubMed
go back to reference Li H, Kantoff PW, Giovannucci E et al (2005) Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65:2498–2504CrossRefPubMed Li H, Kantoff PW, Giovannucci E et al (2005) Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65:2498–2504CrossRefPubMed
go back to reference Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed
go back to reference Liwei L, Chunyu L, Ruifa H (2009) Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 30 July 2009 [Epub ahead of print] Liwei L, Chunyu L, Ruifa H (2009) Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 30 July 2009 [Epub ahead of print]
go back to reference Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
go back to reference Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW (2008) Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29:2335–2340CrossRefPubMed Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW (2008) Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29:2335–2340CrossRefPubMed
go back to reference Millikan RC, Player J, de Cotret AR (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African Americans and whites. Breast Cancer Res 6:R264–R274CrossRefPubMed Millikan RC, Player J, de Cotret AR (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African Americans and whites. Breast Cancer Res 6:R264–R274CrossRefPubMed
go back to reference Rosenblum JS (1996) On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci USA 93:4471–4473CrossRefPubMed Rosenblum JS (1996) On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci USA 93:4471–4473CrossRefPubMed
go back to reference Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F (2003) The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13:145–157CrossRefPubMed Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F (2003) The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13:145–157CrossRefPubMed
go back to reference Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17 Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17
go back to reference Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17 Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17
go back to reference Venkataraman S, Jiang X, Weydert C (2005) Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24:77–89CrossRefPubMed Venkataraman S, Jiang X, Weydert C (2005) Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24:77–89CrossRefPubMed
go back to reference Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–440PubMedCrossRef Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–440PubMedCrossRef
go back to reference Wang LI, Neuberg D, Christiani DC (2004) Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med 46:556–564CrossRefPubMed Wang LI, Neuberg D, Christiani DC (2004) Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med 46:556–564CrossRefPubMed
go back to reference Woodson K, Tangrea JA, Lehman TA et al (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518CrossRefPubMed Woodson K, Tangrea JA, Lehman TA et al (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518CrossRefPubMed
go back to reference Zhong WX (1997) Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14:481–490CrossRefPubMed Zhong WX (1997) Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14:481–490CrossRefPubMed
Metadata
Title
MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects
Authors
Chen Mao
Li-Xin Qiu
Ping Zhan
Kai Xue
Hong Ding
Fang-Bing Du
Jin Li
Qing Chen
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 7/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0742-x

Other articles of this Issue 7/2010

Journal of Cancer Research and Clinical Oncology 7/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine